HGF

HGF

HGF Informations sur la molécule

Molecule Name
Hepatocyte growth factor
Alias de la molécule
HGF,HPTA,SF
Drug Development Progress
Nombre de médicaments cliniques7
Nombre de médicaments commercialisés1
Phase de R&D la plus avancéeApproved
Alias de la cible
EC 3.4.21.7,Hepatocyte Growth Factor (Hepapoietin A; Scatter Factor),EC 3.4.21,HGF,Hepatopoietin-A,Scatter factor,Hepatocyte Growth Factor (Hepapoietin A,Scatter Factor),Fibroblast-Derived Tumor Cytotoxic Factor,Lung Fibroblast-Derived Mitogen,SF,Deafness, Autosomal Recessive 39,Hepatopoietin A,DFNB39,F-TCF,HGFB,Hepatocyte Growth Factor,HPTA
Contexte de la molécule
Hepatocyte growth factor (HGF) is a paracrine cellular growth, motility and morphogenic factor. Activating ligand for the receptor tyrosine kinase MET by binding to it and promoting its dimerization. Hepatocyte growth factor is secreted by mesenchymal cells and acts as a multi-functional cytokine on cells of mainly epithelial origin. Its ability to stimulate mitogenesis, cell motility, and matrix invasion gives it a central role in angiogenesis, tumorogenesis, and tissue regeneration. In addition, HGF has been implicated in a variety of cancers, including of the lungs, pancreas, thyroid, colon, and breast.

HGF Liste de produits

Species
  • Human(4)
Tag
  • Tag Free(2)
  • Fc Tag(1)
  • His Tag(1)
Host
  • HEK293(4)
Conjugate
  • Unconjugated(4)
Grade
  • RUO(2)
  • GMP(1)
  • PG (pre-GMP)(1)
Low Endotoxin
  • Yes(1)
  • No(3)
MoleculeCat. No.Product NameEspèceHostStructurePurityActivitySize&PriceAdd to Cart
HGF
GMP Human HGF Protein
Human
HEK293
SDS-PAGE
CELL BASE

$750.00

50ug
HGF
Human HGF Protein, premium grade
Human
HEK293
MALSSDS-PAGE
ELISACELL BASE

$180.00

20ug
HGF
Human HGF Protein, Fc Tag (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISA

$430.00

100ug
HGF
Human HGF Protein, His Tag, low endotoxin (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISASPRBLICELL BASE

$165.00

20ug
You Have Viewed 1-4 Of 4 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
FosgonimetonNDX-1017; ATH-1017; ATH 1017Phase 3 ClinicalM3 Biotechnology
Alzheimer Disease; Dementia; Lewy Body Disease; Parkinson Disease
Details
RGL-2102RGL-2102; RGL2102Phase 3 ClinicalShanghai Regenelead Therapies Co Ltd
Diabetic Foot; Ischemia; Ulcer; Wound Infection
Details
FiclatuzumabAV-299; SCH-900105Phase 3 ClinicalAveo
Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cholangiocarcinoma; Colonic Neoplasms; Glioblastoma; Head and Neck Neoplasms; Leukemia, Myeloid, Acute; Liver Neoplasms; Lung Neoplasms; Lymphoma; Multiple Myeloma; Oropharyngeal Neoplasms; Pancreatic Neoplasms; Respiratory Tract Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
UmikibartYYB-101; NOV-1105; CLM-101Phase 2 ClinicalYooYoung Pharmaceutical Co Ltd
Colorectal Neoplasms; Solid tumours
Details
ATH-1020ATH-1020Phase 1 ClinicalAthira Pharma Inc
Nerve Degeneration
Details
ATH-1105ATH-1105Phase 1 ClinicalAthira Pharma Inc
Amyotrophic Lateral Sclerosis; Frontotemporal Dementia
Details
Microbiome-optimized autologous stem cell therapy (Biotech Holdings)ClinicalBiotech Holdings
Peripheral Vascular Diseases
Details

Informations sur les médicaments commercialisés

Nom anglaisCode de recherchePhase de R&DEntreprisePlus ancien nom de marquePays d'approbation le plus ancienIndication la plus ancienneSociété d'approbation la plus ancienneDate d'approbation la plus ancienneIndicationEssai clinique
Beperminogene perplasmidAMG-0001-01; AMG-0001; DS-992; TREAT-HGFApprovedAnges Mg, Osaka UniversityCollategeneJapanPeripheral Arterial Disease; IschemiaAnges Inc, null2019-03-01
Arterial Occlusive Diseases; Atherosclerosis; Foot Ulcer; Ischemia; Peripheral Arterial Disease; Peripheral Vascular Diseases; Ulcer; Vascular Diseases
Details
Customer Reviews